title: Evolving role of 5-alpha reductase inhibitors in chemoprevention.
authors.forename: Wesley M
authors.initials: WM
authors.lastname: White
authors.forename: Edward D
authors.initials: ED
authors.lastname: Kim
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use; D000068538:Dutasteride; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011322:Primary Prevention / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride
references.citation: J Urol. 2009 Apr;181(4):1642-57
references.pmid: 19249063
references.citation: J Clin Oncol. 2009 Jul 10;27(20):e22; author reply e23
references.pmid: 19487370
references.citation: Cancer. 2008 Mar 1;112(5):1058-65
references.pmid: 18186497
references.citation: N Engl J Med. 2010 Apr 1;362(13):1192-202
references.pmid: 20357281
references.citation: N Engl J Med. 2003 Jul 24;349(4):366-81
references.pmid: 12878745
references.citation: Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents
references.pmid: 20152515
references.citation: N Engl J Med. 2003 Jul 17;349(3):215-24
references.pmid: 12824459
references.citation: Cancer Prev Res (Phila). 2008 Aug;1(3):167-73
references.pmid: 19138952
references.citation: J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33
references.pmid: 16912265